Novartis/gene therapy: corporate DNA

The control premium for AveXis is hefty, but should be given the benefit of the doubt
Source: - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: 21 February 2019Source: Cell, Volume 176, Issue 5Author(s): Shashi Gujar, John Bell, Jean-Simon DialloOncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.
Source: Cell - Category: Cytology Source Type: research
Abstract The present study aimed to examine the apoptotic effects of adenovirus (ADV)-mediated herpes simplex virus thymidine kinase (ADV-TK) combined with ganciclovir (GCV) in tissues obtained from patients with hepatocellular carcinoma in order to provide a theoretical basis for the development of this gene therapy program. Apoptosis detection was conducted using the terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling assay and the apoptosis index was compared between the experimental; and control groups. Furthermore, the protein expression levels of caspase-3, B-cell lymphoma-2 (Bcl-2), Bcl-2...
Source: Herpes - Category: Infectious Diseases Authors: Tags: Exp Ther Med Source Type: research
This study is a retrospective review of Cochrane Vascular Specialized Register, MEDLINE Ovid, Embase Ovid, CINAHL, and AMED through November 27, 2017.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Tags: Gene therapy to treat peripheral arterial disease —not yet Source Type: research
Conclusions:In light of promising preclinical data that may rapidly expand in a close future, biomaterial-guided viral gene therapy has a strong potential for translation in the field of human orthopaedic regenerative medicine.
Source: Tissue Engineering and Regenerative Medicine - Category: Biotechnology Source Type: research
Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human, Published online: 21 February 2019; doi:10.1038/s41417-019-0087-9Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
CCR Grand Rounds F. Stephen Hodi, M.D., is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College in 1992. Dr. Hodi completed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania and Medical Oncology training at Dana-Farber cancer Institute where he joined the faculty in 1995. His research focuses on gene therapy, the development of immune therapies, and first-in-human studies for malignant melanoma...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Author Correction: Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori, Published online: 20 February 2019; doi:10.1038/s41417-019-0086-xAuthor Correction: Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Using the gene-editing technology CRISPR, scientists at the University of North Carolina switched on a muted gene in mice embryos, which were then born with no trace of the disorder.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Publication date: Available online 18 February 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Idoia Gallego, Ilia Villate-Beitia, Gema Martínez-Navarrete, Margarita Menéndez, Tania López-Méndez, Cristina Soto-Sánchez, Jon Zárate, Gustavo Puras, Eduardo Fernández, José Luis PedrazAbstractLow transfection efficiency is a major challenge to overcome in non-viral approaches to reach clinical practice. Our aim was to explore new strategies to achieve more efficient non-viral gene therapies for clinical applications and in particular, for retinal d...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
In its first year, Luxturna — the first Food and Drug Administrative-approved gene therapy treatment for an inherited disease — generated $27 million in sales for Philadelphia-based Spark Therapeutics. Spark said it has shipped 75 vials of Luxturna, a one-time gene therapy used to treat adult and pediatric patients with v ision loss caused by inherited retinal dystrophy from a genetic mutation. The inherited retinal disorder, which leads to blindness if untreated, afflicts an estimated 1,000…
Source: Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
More News: Gene Therapy | Genetics